The prognostic value of ferritinemia level in patients with chronic hepatitis C
Abstract
Aim of investigation. To study the effect of various factors on the blood ferritin level in patients with chronic hepatitis C (CHC) and baseline ferritin level on treatment response rate of pegilated interferon α-2a (PEG-IFN α-2a) combined to ribavirin (RBV).
Material and methods. The level of ferritin was determined in 67 patients with CHC by two solid-phase sandwich immunoenzymatic assays. In 32 patients, who received PEG-IFN α-2a and RBV, it was determined on starting point, on the 12th week and after termination of therapy. Logistical regression has been applied to study effect of ferritin and other variables on frequency of sustained virologic response (SVR).
Results. Elevated ferritin level was revealed in 34,3% of patients, and it was significantly higher in men, than in women (326,0±38,4 vs 108,2±44,7 ng/dl, p <0,05). The average level of ferritin in the patients included in PEGIFN α-2a and RBV group, prior to onset of treatment was normal (241,4±33,1), on the 12th week of treatment it turn to be elevated in 90% of patients with average level of 703,5±133,4 ng/dl (p=0,009 at comparison to initial level), and after the end of treatment course elevation was observed in 66,6% of patients at average value of 473,6±96,3 ng/dl (p=0,044 at to starting point, p=0,07 at comparison to the 12-th week data). By comparison of average levels of ferritin in patients with SVR at intake of PEG-IFN α-2a in combination to RBV and in patients without SVR the difference was also apparent, especially at the 12th week.
Conclusions. Application of logistical regression analysis demonstrated, that the baseline ferritin level is independent predictor of sustained virologic response at treatment by pegilated interferon α-2a with ribavirin.
About the Authors
N. C. Sargsyants
Clinical center «Armenicum»
Armenia
Armenia
E. H. Grigoryan
Post-treatment department of the Scientific research institute of balneotherapeutics and physical medicine of Ministry of Healthcare of the Republic of Armenia
Armenia
Armenia
References
1. Буеверов А.О., Маевская М.В. Хронический гепатит С и сочетанная патология печени // Фарматека. – 2008. – № 13. – С. 16–21.
2. Жданов К.В., Гусев Д.А., Чирский В.С. и др. Характеристика метаболизма железа у больных хроническим гепатитом С // Клин. перспективы гастоэнтерол. гепатол. – 2009. – № 1. – С. 10–17.
3. Маммаев С.Н., Лукина Е.А., Павлов Ч.С. и др. Показатели метаболизма железа и антиоксидантная активность сыворотки крови у больных хроническим вирусным гепатитом С // Рос. журн. гастоэнтерол. гепатол. колопроктол. – 2003. – Т. 13, № 2. – С. 32–36.
4. Barbaro G., di Lorenzo G., Ribersani M. et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype // J. Hepatol. – 1999. – Vol. 30 (5). – Р. 774–782.
5. Ferrara F., Ventura P., Vegetti A. et al. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C // Am. J. Gastroenterol. – 2009. – Vol. 104 (3). – P. 605–616.
6. Garrido Serrano A., Guerrero Igea F.J., Lepe Jimenez J.A. et al. Hepatitis C virus infection, increased serum ferritin and hyperinsulinemia // Rev. Esp. Enferm. Dig. – 2001. – Vol. 93 (10). – P. 639–648.
7. Hofer H., Österreicher C., Jessner W. et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C // J. Hepatol. – 2004. – Vol. 40 (6). – P. 1018–1022.
8. Rulyak S.J., Eng S.C., Patel K. et al. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin // Am. J. Gastroenterol. – 2005. – Vol. 100 (2). – Р. 332–337.
Review
For citations:
Sargsyants N.C., Grigoryan E.H. The prognostic value of ferritinemia level in patients with chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;23(3):56-59. (In Russ.)
Views:
85
Email this article 
